Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 34

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 34
---
; |

| • | the need to hire additional personnel and the combined company’s ability to attract and retain such personnel; |

| • | the ability to protect and enhance the combined company’s products and intellectual property, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and the combined company’s ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights; |

| • | any statements concerning developments and projections relating to the combined company’s competitors or industry; |

| • | Channel’s, LNHC’s, or the combined company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |

| • | any statements concerning Channel’s, LNHC’s, or the combined company’s financial performance; |

17

TABLE OF CONTENTS

| • | any statements regarding expectations concerning Channel’s or LNHC’s relationships and actions with third parties, including any license and collaborations with such third parties; |

| • | future regulatory, judicial and legislative changes in Channel’s or LNHC’s industry in the United States, Europe, and other jurisdictions; |

| • | the ability of the combined company’s clinical trials to demonstrate safety and efficacy of the combined company’s product candidates, and other positive results; |

| • | the combined company’s ability to utilize its proprietary drug discovery platform to develop a pipeline of product candidates to address unmet needs in rare skin disease indications; |

| • | the outcome of clinical trials of the combined company’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; |

| • | the timing of availability of data from the combined company’s clinical trials; |

| • | the combined company’s plans to research, develop and commercialize its current and future product candidates; |

| • | the combined company’s ability to protect its intellectual property and proprietary technologies; |

| • | the combined company’s reliance on third parties, contract manufacturers, and contract research organizations; |

| • | the combined company’s ability to develop and advance current product candidates and programs into, and successfully complete, clinical studies; |

| • | the combined company’s manufacturing, commercialization, and marketing capabilities and strategy; |

| • | the size of the market opportunity for the combined company’s product candidates, including estimates of the number of patients who suffer from the diseases the combined company is targeting; |

| • | expectations regarding potential for accelerated approval or other expedited regulatory designation; |

| • | the combined company’s